This website uses cookies and similar technologies to deliver its services, to analyse and improve performance and to provide personalised content and advertising. Information about your use of this website will be shared with Google and other third parties. Read our privacy policy.
2013-11-14T00:00:00Z
$1.7bn deal reinforces firm’s focus on core pharmaceuticals
